1.
Anticancer Res
; 13(5C): 1901-4, 1993.
Article
in English
| MEDLINE
| ID: mdl-8267398
ABSTRACT
Serum TPS, CA 15-3 and CEA levels were measured in 31 women when progressive metastatic disease was established according to UICC criteria. A method was developed to apply these serum tumor markers in order to measure the short-term effect of the treatment. Using strict criteria, whereby an increase of the markers of more than 25% indicated progressive disease and a decrease of more than 50% indicated a positive effect of the treatment, TPS (which measures tumoral activity) was shown to be a more sensitive and earlier marker for measuring treatment response than CA 15-3 and CEA (which measure tumor mass).